Research
Current research, translated.
New studies on Type 2 Diabetes treatments — what they found and what they mean for the people taking these drugs. Plain-language up top, the full detail underneath.
Latest · Single-study breakdown
Foundayo's ACHIEVE-4 cardiovascular data: 57% lower all-cause death, non-inferior MACE, and meaningful A1C/weight benefits
A large 52-week trial of the new pill Foundayo (orforglipron) vs insulin cleared its heart-safety test — and fewer deaths happened on the drug. What the numbers can and can't tell you.
Evidence roundup
2026 Semaglutide Trials: SELECT, FLOW, SOUL
Single-study breakdown
The Single Amino Acid That May Explain Why GLP-1 Drugs Keep Working
Regulatory news
Orforglipron gains UK regulatory approval for type 2 diabetes
Evidence roundup
ADA 2026: the next wave of diabetes and obesity drugs, explained
Evidence roundup
Two new GLP-1 trials, one direction: what mazdutide and orforglipron mean together
Single-study breakdown
What the mazdutide obesity trial (GLORY-2) actually showed
Single-study breakdown
An oral GLP-1 added to insulin: what the orforglipron trial actually showed